The therapeutic potential of natural medicine puerarin for depression

Yuchao Guo

doi:10.62051/e74tfc16

Authors

Yuchao Guo

DOI:

https://doi.org/10.62051/e74tfc16

Keywords:

puerarin depression neuroinflammation brain-gut axis.

Abstract

The incidence of depression has steadily increased in recent years, making it one of the most prevalent mental disorders. As the pursuit of new antidepressant drugs has attracted wide attention in the pharmaceutical community, the therapeutic effects of traditional Chinese medicine have also been extensively explored. Puerarin is commonly used as a vasodilator in the treatment of coronary heart disease including angina and myocardial ischemia, cerebral infarction, retinal vein occlusion, and sudden deafness. However, the potential of puerarin in the treatment of depression is very great, so this article reviews the latest research progress of puerarin in the mechanism of depression in recent years, and discusses its application prospect in depression. In addition, we also discuss the related pathological mechanism of depression, which provides new insights for further understanding of depression. However, despite the great potential of puerarin, further studies are needed to elucidate its specific mechanism of action and evaluate its effectiveness in human subjects.

Downloads

Download data is not yet available.

References

[1] M.M. Aguirre-García, A. Amedei, L.A. Constantino-Jonapa, E. Tesoro-Cruz, A.P. Gómez-García, L. Segura-Real, S. Reyes-Martínez, Neuroinflammation, Microbiota-Gut-Brain Axis, and Depression: The Vicious Circle, Journal of Integrative Neuroscience 22(3) (2023).

[2] S. Ran, R. Peng, Q. Guo, J. Cui, G. Chen, Z. Wang, Bupleurum in Treatment of Depression Disorder: A Comprehensive Review, Pharmaceuticals 17(4) (2024).

[3] J.B. Dwyer, A. Aftab, R. Radhakrishnan, A. Widge, C.I. Rodriguez, L.L. Carpenter, C.B. Nemeroff, W.M. McDonald, N.H. Kalin, Hormonal Treatments for Major Depressive Disorder: State of the Art, American Journal of Psychiatry 177(8) (2020) 686-705.

[4] T. Spellman, C. Liston, Toward Circuit Mechanisms of Pathophysiology in Depression, American Journal of Psychiatry 177(5) (2020) 381-390.

[5] X. Liu, R. Huang, J. Wan, Puerarin: a potential natural neuroprotective agent for neurological disorders, Biomedicine & Pharmacotherapy 162 (2023).

[6] B. Wang, Y. Teng, Y. Li, S. Lai, Y. Wu, S. Chen, T. Li, X. Han, H. Zhou, Y. Wang, Z. Lu, H. Li, Y. Ding, L. Ma, M. Zhao, X. Wang, Evidence and Characteristics of Traditional Chinese Medicine for Coronary Heart Disease Patients With Anxiety or Depression: A Meta-Analysis and Systematic Review, Frontiers in Pharmacology 13 (2022).

[7] Y.-W. Zhang, L.-H. Kong, L. Wang, Y. Li, J. Li, Y.-J. Du, C.-C. Yu, Neuroprotective Mechanisms of Puerarin in Central Nervous System Diseases: Update, Aging and disease 13(4) (2022).

[8] L. Cui, S. Li, S. Wang, X. Wu, Y. Liu, W. Yu, Y. Wang, Y. Tang, M. Xia, B. Li, Major depressive disorder: hypothesis, mechanism, prevention and treatment, Signal Transduction and Targeted Therapy 9(1) (2024).

[9] Y.-S. Wang, C.-Y. Shen, J.-G. Jiang, Antidepressant active ingredients from herbs and nutraceuticals used in TCM: pharmacological mechanisms and prospects for drug discovery, Pharmacological Research 150 (2019).

[10] R.M. Hirschfeld, History and evolution of the monoamine hypothesis of depression, J Clin Psychiatry 61 Suppl 6 (2000) 4-6.

[11] I. Pastis, M.G. Santos, A. Paruchuri, Exploring the role of inflammation in major depressive disorder: beyond the monoamine hypothesis, Frontiers in Behavioral Neuroscience 17 (2024).

[12] L. Hantsoo, K.M. Jagodnik, A.M. Novick, R. Baweja, T.L. di Scalea, A. Ozerdem, E.C. McGlade, D.I. Simeonova, S. Dekel, S.L. Kornfield, M. Nazareth, S.J. Weiss, The role of the hypothalamic-pituitary-adrenal axis in depression across the female reproductive lifecycle: current knowledge and future directions, Frontiers in Endocrinology 14 (2023).

[13] A. Wu, J. Zhang, Neuroinflammation, memory, and depression: new approaches to hippocampal neurogenesis, Journal of Neuroinflammation 20(1) (2023).

[14] N. Barden, Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression, J Psychiatry Neurosci 29(3) (2004) 185-93.

[15] S. Kumar Mudgal, S. Nath, J. Chaturvedi, S. Kumar Sharma, J. Joshi, Neuroplasticity in Depression: A Narrative Review with Evidence-Based Insights, Psychiatria Danubina 34(3) (2022) 390-397.

[16] S. Liang, X. Wu, X. Hu, T. Wang, F. Jin, Recognizing Depression from the Microbiota–Gut–Brain Axis, International Journal of Molecular Sciences 19(6) (2018).

[17] S. Boku, S. Nakagawa, H. Toda, A. Hishimoto, Neural basis of major depressive disorder: Beyond monoamine hypothesis, Psychiatry and Clinical Neurosciences 72(1) (2017) 3-12.

[18] A.N. Tartt, M.B. Mariani, R. Hen, J.J. Mann, M. Boldrini, Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications, Molecular Psychiatry 27(6) (2022) 2689-2699.

[19] B. Guo, M. Zhang, W. Hao, Y. Wang, T. Zhang, C. Liu, Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression, Translational Psychiatry 13(1) (2023).

[20] E. Won, K.-S. Na, Y.-K. Kim, Associations between Melatonin, Neuroinflammation, and Brain Alterations in Depression, International Journal of Molecular Sciences 23(1) (2021).

[21] E. Sarno, A.J. Moeser, A.J. Robison, Neuroimmunology of depression, Advances in Immunopharmacology2021, pp. 259-292.

[22] J.S. Generoso, V.V. Giridharan, J. Lee, D. Macedo, T. Barichello, The role of the microbiota-gut-brain axis in neuropsychiatric disorders, Brazilian Journal of Psychiatry 43(3) (2021) 293-305.

[23] A. Góralczyk-Bińkowska, D. Szmajda-Krygier, E. Kozłowska, The Microbiota–Gut–Brain Axis in Psychiatric Disorders, International Journal of Molecular Sciences 23(19) (2022).

[24] F. Zhu, H. Tu, T. Chen, The Microbiota–Gut–Brain Axis in Depression: The Potential Pathophysiological Mechanisms and Microbiota Combined Antidepression Effect, Nutrients 14(10) (2022).

[25] X. Song, W. Wang, S. Ding, X. Liu, Y. Wang, H. Ma, Puerarin ameliorates depression-like behaviors of with chronic unpredictable mild stress mice by remodeling their gut microbiota, J Affect Disord 290 (2021) 353-363.

[26] X. Song, W. Wang, S. Ding, Y. Wang, L. Ye, X. Chen, H. Ma, Exploring the potential antidepressant mechanisms of puerarin: Anti-inflammatory response via the gut-brain axis, J Affect Disord 310 (2022) 459-471.

[27] L. Thi Huong Nguyen, M.-J. Choi, H.-M. Shin, I.-J. Yang, T. Satou, Seungmagalgeun-Tang, a Traditional Herbal Formula, Alleviates Skin Inflammation and Depression-Like Behavior in Atopic Dermatitis Mice under Sleep Deprivation Conditions, Evidence-Based Complementary and Alternative Medicine 2022 (2022) 1-15.

[28] Y. Liu, Z. Hu, J. Wang, Y. Liao, L. Shu, Puerarin alleviates depressive-like behaviors in high-fat diet-induced diabetic mice via modulating hippocampal GLP-1R/BDNF/TrkB signaling, Nutr Neurosci 26(10) (2023) 997-1010.

[29] L.-N. Gao, M. Yan, L. Zhou, J.a. Wang, C. Sai, Y. Fu, Y. Liu, L. Ding, Puerarin Alleviates Depression-Like Behavior Induced by High-Fat Diet Combined With Chronic Unpredictable Mild Stress via Repairing TLR4-Induced Inflammatory Damages and Phospholipid Metabolism Disorders, Frontiers in Pharmacology 12 (2021).

[30] J. Zhao, Y. Jia, W. Zhao, H. Chen, X. Zhang, F.Y. Ngo, D. Luo, Y. Song, L. Lao, J. Rong, X. Shi, Botanical Drug Puerarin Ameliorates Liposaccharide-Induced Depressive Behaviors in Mice via Inhibiting RagA/mTOR/p70S6K Pathways, Oxidative Medicine and Cellular Longevity 2021 (2021) 1-16.

[31] J. Zhao, D. Luo, Z. Liang, L. Lao, J. Rong, Plant Natural Product Puerarin Ameliorates Depressive Behaviors and Chronic Pain in Mice with Spared Nerve Injury (SNI), Mol Neurobiol 54(4) (2017) 2801-2812.

[32] J. Cheng, M. Chen, J.X. Zhu, C.F. Li, Q.P. Zhang, D. Geng, Q. Liu, L.T. Yi, FGF-2 signaling activation in the hippocampus contributes to the behavioral and cellular responses to puerarin, Biochem Pharmacol 168 (2019) 91-99.

[33] C.C. Huang, M.H. Tsai, Y.C. Wu, K.T. Chen, H.W. Chuang, Y. Chen, G.W. Tseng, P.I. Fu, I.H. Wei, Activity Dependent Mammalian Target of Rapamycin Pathway and Brain Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Effects of Puerarin, Am J Chin Med (2018) 1-16.